Close Menu

NEW YORK (GenomeWeb) – ERS Genomics has licensed its CRISPR-Cas9 genome editing technology to Danish non-profit research services firm Bioneer, the organizations said today.

Dublin-based ERS Genomics was founded to provide access to CRISPR-Cas9 intellectual property held by Emmanuelle Charpentier for applications other than human disease treatment. This CRISPR IP is shared between her, Jennifer Doudna and the University of California, and the University of Vienna, and is separate from genome editing patents held by the Broad Institute.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.

The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.

New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.

In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.